|
Press Releases |
|
|
|
Tuesday, December 1, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Monday, November 30, 2020 |
|
BioVaxys Provides Viral Vaccine Platform Program Update |
BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
Wednesday, November 11, 2020 |
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
Monday, November 2, 2020 |
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
王朝酒业公布2023年全年业绩
Mar 28, 2024 17:45 HKT/SGT
|
|
|
王朝酒業公佈2023年全年業績
Mar 28, 2024 17:42 HKT/SGT
|
|
|
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
东软教育:内生高质量发展 数字化赋能打开长远增长空间
Mar 28, 2024 16:45 HKT/SGT
|
|
|
東軟教育:內生高質量發展 數字化賦能打開長遠增長空間
Mar 28, 2024 16:42 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
|
|
|
浙江沪杭甬:业绩稳健向好 积极回馈股东 分红总额增长17.7%
Mar 28, 2024 15:43 HKT/SGT
|
|
|
浙江滬杭甬:業績穩健向好 積極回饋股東 分紅總額增長17.7%
Mar 28, 2024 15:37 HKT/SGT
|
|
|
2023年收入、利潤實現「雙增長」 復星下一步:「深挖礦」,穩盈利
Mar 28, 2024 15:31 HKT/SGT
|
|
|
Fosun's Next Step: "Deep Mining" for Stable Profits
Mar 28, 2024 15:26 HKT/SGT
|
|
|
国际债券持有人特别团体(“持有人特别团体”)指示受托人 向香港上市公司希教国际控股(1765.HK)送达清盘呈请书
Mar 28, 2024 15:21 HKT/SGT
|
|
|
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT/SGT
|
|
|
IGG集團全年扭虧為盈 下半年盈利逾4.3億港元
Mar 28, 2024 14:33 HKT/SGT
|
|
|
Turning Loss into Profit in 2023: IGG Achieved over HK$430 million in 2H23
Mar 28, 2024 14:25 HKT/SGT
|
|
|
朝雲集團2023年營收純利雙增,派息分紅比例持續走高
Mar 28, 2024 14:10 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|